GC reports positive outlook on clinical performance
of EQUIA Forte
LEUVEN, Belgium: After the success of the EQUIA restorative system, introduced in 2007, GC made the next great leap with EQUIA Forte. A two-year multicentre clinical study confirmed that EQUIA Forte is a suitable material for medium to large Class II restorations.
Clinical studies are essential for assessing the performance of dental materials; therefore, a five-year clinical study was initiated in 2015, the same year that EQUIA Forte, a glass hybrid restorative material, was launched. This long-term trial compared EQUIA Forte with a nano-hybrid composite (Tetric EvoCeram, Ivoclar Vivadent) in medium to large Class II restorations.
The interim two-year results showed similar clinical performance for both materials, confirming that EQUIA Forte is suitable and demonstrated excellent performance as a long-term restorative material. Furthermore, at the end of the two years, virtually no differences were observed between the two materials in any of the aesthetic, functional or biological properties tested. The study was led by Dr Ivana Miletić, a professor in the Department of Endodontics and Restorative Dentistry at the University of Zagreb School of Dental Medicine in Croatia, working with a team of highly regarded researchers from four European universities: Dr Anja Baraba (University of Zagreb), Drs Matteo Basso and Maria Giulia Pulcini (University of Milan in Italy), Prof. Dejan Marković and Dr Tamara Perić (University of Belgrade in Serbia), Dr Çigdem Atalayin Özkaya and Prof. Lezize Sebnem Türkün (Ege University in Izmir in Turkey).
This long-term split mouth (equal allocation ratio) prospective multicentre randomised clinical study enrolled 180 patients (mean age: 34.6 years) identified as being in need of two Class II two-surface restorations in the molar region of the same jaw. Impressions were taken before and after cavity preparation, as well as after the final restoration. These impressions were subsequently scanned for further wear evaluation at the third and fifth year of the study, and a clinical evaluation was performed using the FDI World Dental Federation clinical criteria for the evaluation of direct and indirect restorations.
The estimated survival rates at the two-year recall were 93.6% (EQUIA Forte) and 94.5% (Tetric EvoCeram), showing no significant differences between the two materials. These excellent results prove the clinical efficacy of glass hybrids such as EQUIA Forte as long-term restorative materials.
The study, titled “Clinical performance of a glass-hybrid system compared with a resin composite in the posterior region: Results of a 2-year multicenter study”, was published on 29 May 2020 in The Journal of Adhesive Dentistry.